FDA Initiates Class III Recall for Rising Pharma's Diflorasone Diacetate Ointment Due to Impurity Failures
Rising Pharma Holdings, Inc. has initiated a Class III recall (D-0599-2024) for 868 tubes of Diflorasone Diacetate Ointment, USP, 0.05%, due to failed impurity specifications at 12-month stability testing. This nationwide recall, impacting lot DI2303B, underscores critical quality control vulnerabilities for pharmaceutical procurement and regulatory affairs teams. Businesses must assess supply chain continuity and review quality assurance protocols for topical corticosteroid products.
FDA Initiates Class III Recall for Rising Pharma's Diflorasone Diacetate Ointment
On June 24, 2024, Rising Pharma Holdings, Inc., based in East Brunswick, NJ, initiated a voluntary Class III recall, identified as D-0599-2024, for its Diflorasone Diacetate Ointment, USP, 0.05%. This critical action was prompted by the product's failure to meet established impurity and degradation specifications during 12-month stability testing. Specifically, lot number DI2303B, with an expiration date of December 31, 2024, was found to contain impurity levels exceeding the acceptable limits. The recall impacts 868 tubes of the 60g presentation (NDC 64980-124-60), which were distributed nationwide across the USA. For procurement directors and supply chain VPs, this event necessitates an immediate review of inventory for the affected lot to prevent distribution of non-conforming product. Failure to promptly identify and quarantine recalled stock can lead to significant logistical costs, potential regulatory penalties, and reputational damage. Regulatory affairs heads must ensure that all internal procedures align with FDA recall protocols, including communication with downstream partners and proper disposition of affected units.
Quality Control Lapses: Impurity Specifications Failure for Topical Corticosteroid
The core issue driving this recall is the failure of Diflorasone Diacetate Ointment to maintain its impurity profile over time, specifically at the 12-month stability mark. Diflorasone Diacetate is a potent topical corticosteroid used for various dermatological conditions, and the presence of elevated impurities or degradation products can compromise both the product's efficacy and patient safety. Degradation products may reduce the active pharmaceutical ingredient's concentration, leading to suboptimal therapeutic outcomes, or, more critically, introduce unknown toxicological risks. The product was manufactured by Lyne Laboratories, Inc. in Brockton, MA, for Rising Pharmaceuticals, Inc. This distinction is crucial for procurement and quality assurance teams, as it highlights the importance of rigorous contract manufacturing oversight. Business development executives must understand that such quality failures, even for a Class III recall, can erode trust in a product line and impact future market access or partnership opportunities. Robust stability programs and stringent quality agreements with contract manufacturers are paramount to prevent such costly and disruptive events, ensuring that products like Diflorasone Diacetate consistently meet their labeled specifications throughout their shelf life.
Supply Chain Disruption: Nationwide Impact on Diflorasone Diacetate Availability
The nationwide distribution of the 868 recalled tubes of Diflorasone Diacetate Ointment, USP, 0.05%, lot DI2303B, poses an immediate challenge for pharmaceutical distributors, wholesalers, and healthcare providers across the United States. While 868 tubes may seem a modest quantity, the recall of a specific lot can create localized stockouts or temporary supply constraints, particularly for a product used in chronic or acute dermatological treatments. Procurement directors must swiftly identify if their distribution channels received the affected lot and initiate reverse logistics procedures. This involves not only the physical retrieval of the product but also managing the associated administrative burden and financial implications, including potential credit processing and disposal costs. For business development executives, this disruption can lead to a temporary loss of market share if alternative products are readily available and quickly adopted by prescribers and pharmacies. Ensuring robust traceability systems and efficient recall management protocols are critical for minimizing the operational and financial impact of such events on the entire supply chain, from manufacturer to patient.
Market Landscape and Sourcing Strategy for Topical Corticosteroids
The recall of Rising Pharma's Diflorasone Diacetate Ointment highlights the broader challenges within the market for generic topical corticosteroids. While the provided knowledge graph does not specify alternative suppliers for Diflorasone Diacetate, procurement teams must proactively identify and qualify diverse sourcing options for critical molecules to mitigate supply chain risks. Relying on a single manufacturer or a limited pool of suppliers for essential drugs like Diflorasone Diacetate, which is used to manage inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, can expose businesses to significant vulnerabilities during quality events. The qualification process for new pharmaceutical suppliers is extensive, involving comprehensive audits, analytical testing, and regulatory documentation, often requiring 12-24 months. Therefore, strategic sourcing should prioritize geographic diversity and a robust pipeline of pre-qualified backup suppliers. For regulatory affairs heads, understanding the regulatory landscape for new supplier approvals is crucial to ensure a seamless transition and avoid market shortages should a primary supplier face compliance issues. This proactive approach safeguards product availability and minimizes commercial disruption.
Regulatory Scrutiny and Compliance Post-Recall for Rising Pharma
While the provided intelligence does not detail a prior regulatory history for Rising Pharma Holdings, Inc., this Class III recall for Diflorasone Diacetate Ointment will undoubtedly draw increased scrutiny from the FDA. A product quality failure, particularly one related to impurity specifications and stability, signals potential deficiencies in the company's Quality Management System. Regulatory affairs heads must prepare for a thorough internal investigation, culminating in a comprehensive Corrective and Preventive Action (CAPA) plan. This plan must address the root cause of the impurity exceedance, whether it stems from raw material quality, manufacturing process control, packaging interactions, or inadequate stability study design. The FDA will expect detailed evidence of these corrective actions and their effectiveness. Failure to implement robust CAPA measures can escalate regulatory actions, potentially leading to more severe classifications in future events or even broader enforcement actions. For business development executives, a strong, demonstrable commitment to quality and regulatory compliance post-recall is essential to maintain market confidence and ensure the long-term viability of their product portfolio, especially for molecules like Diflorasone Diacetate.